Get in touch

SFDA Innovative Medical Device Pathway

Empowering international manufacturers to bring cutting-edge medical technologies — AI diagnostics, digital health, SaMD, and biotech — into the KSA & GCC market with precision and confidence

Built for Innovators at the Frontier of MedTech

From AI-powered diagnostic platforms to bio-printed matrices, we guide international manufacturers through Saudi Arabia’s high-risk innovative device regulatory landscape.

AI Diagnostics Developers

Navigate SFDA classification and market access for artificial intelligence-powered diagnostic and imaging platforms.

SaMD & Digital Health

Establish compliant market access for Software as a Medical Device and connected digital health ecosystems in KSA & GCC.

Biotech Device Manufacturers

Strategic compliance for bio-printed matrices, cell-selection platforms, and advanced biologic-device combination systems.

International Manufacturers

Support the localization of clinical trials and the manufacturing of innovative medical technology or market access in the KSA market.

Five Pillars of Innovative Device Market Access

Structured, expert-led interventions covering the full spectrum of innovative medical device regulatory requirements for the KSA market.

Innovative MedTech Pathways

Supporting international manufacturers of AI diagnostics, digital health ecosystems, and SaMD to establish clear, compliant market access within KSA & GCC.

Biotechnology Convergence

Strategic compliance mapping for bio-printed matrices, cell-selection platforms, and advanced biologic-device combination systems regulated as medical devices.

Technical File Assessment

Comprehensive dossier reviews translating advanced clinical data, cybersecurity parameters, and biocompatibility profiles into robust SFDA-ready submissions.

Cybersecurity & Digital Compliance

Building threat assessments, software lifecycle security protocols, and post-market patch management frameworks for connected and AI-enabled devices under SFDA mandates.

GCC Mutual Recognition & Market Expansion

Leveraging SFDA authorization as a gateway to accelerate multi-market entry across the GCC through mutual recognition pathways with minimal regulatory duplication.

How We Work

A structured, expert-led approach to bringing your innovative medical device to the Saudi and GCC market efficiently.

Assess

Device review, technology classification & risk tier mapping

Map

SFDA pathway strategy & regulatory framework selection

Build

Technical file, clinical data & cybersecurity dossier assembly

Submit

SFDA submission management & authority liaison

Authorize

Market authorization & post-market lifecycle support

Key Deliverables

Clear outputs that drive compliance, reduce risk, and accelerate your time to market.

01

Innovative Device Classification Report

SFDA risk classification, regulatory category determination, and pathway recommendation for your device.

02

AI / SaMD Regulatory Strategy

Tailored market access roadmap for AI diagnostics, digital health platforms, and Software as a Medical Device.

03

Biotech Compliance Mapping

Strategic compliance framework for bio-printed matrices, cell-selection platforms, and combination biologic-device systems.

04

Technical File Assessment Report

Comprehensive dossier review translating clinical data, cybersecurity parameters, and biocompatibility into SFDA-ready submissions.

05

Cybersecurity Compliance Package

Full cybersecurity parameter documentation for connected devices and digital health systems per SFDA requirements.

Build a Complete Regulatory Ecosystem .

LexoraMed provides integrated regulatory support across Saudi Arabia, GCC, and global markets — helping manufacturers move from strategy to authorization with confidence and clarity.

Medical Device Market Authorization

Advisory on securing MDMA, SFDA approvals, and global authorization pathways for regional and international market entry.

Read More

Technical File Assessment

Leading comprehensive reviews of innovative device dossiers, successfully translating advanced clinical data, cybersecurity parameters, and biocompatibility profiles into robust regulatory submissions.

Read More

Post-Market Surveillance

Ongoing compliance, vigilance, safety monitoring, reporting, and lifecycle support after market authorization.

Read More

Frequently Asked Questions

Clear answers to the most common regulatory and compliance questions manufacturers ask before entering Saudi Arabia and global markets.

How does SFDA classify AI-powered diagnostic devices? +
AI diagnostics are typically classified as SaMD under SFDA's medical device framework, with risk classification based on the intended use and the severity of the condition being diagnosed. High-risk AI diagnostics (e.g. cancer detection) generally fall under Class C or D, requiring extensive clinical evidence and technical file documentation.
Does the SFDA have a specific pathway for Software as a Medical Device (SaMD)? +
Yes. The SFDA has aligned its SaMD framework with IMDRF guidance. SaMD products must be registered through the SFDA's electronic system (Ghad) with specific technical and clinical documentation requirements dependent on their risk classification and intended clinical function.
Are biotechnology combination products treated as medical devices by the SFDA? +
It depends on the primary mode of action. If the primary function is achieved through the device component, the product is regulated as a medical device under the SFDA. LexoraMed conducts a formal primary mode of action analysis to determine the correct regulatory category before any submission.
What cybersecurity documentation is required for connected medical devices? +
The SFDA requires manufacturers of connected devices to submit a cybersecurity documentation package covering threat and vulnerability assessment, security risk management, software development lifecycle security, and post-market patch management protocols. LexoraMed builds this package as part of the technical file assessment.